We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Another Blow: FDA Adcomm Recommends Against Fabre-Kramer’s Depression Drug
Another Blow: FDA Adcomm Recommends Against Fabre-Kramer’s Depression Drug
An FDA advisory committee Tuesday erected another roadblock for getting Fabre-Kramer’s depression candidate gepirone on the market, recommending against approving a potential therapy whose fate has been in limbo for two decades.